Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
Hoyoung Maeng(National Cancer Institute), Jay A. Berzofsky(National Cancer Institute), Lee England(National Cancer Institute), Lauren V. Wood(National Cancer Institute), Mohammadhadi Bagheri(National Institutes of Health Clinical Center), Seth M. Steinberg(National Institutes of Health), Giselle Saurez Martínez(National Institutes of Health Clinical Center), David F. Stroncek(Yale University), Brittni N. Moore(Johns Hopkins University), Masaki Terabe(National Cancer Institute), Santhana Webb(National Cancer Institute), John C. Morris(Alzheimer's Association), Svetlana Pack(National Cancer Institute)
Cited by 8
Related Papers
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
|Clinical Cancer Research|2005|371
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|327
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|312